

## DAFTAR PUSTAKA

1. Ceylan B, et al. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection. *Wien Klin Wochenschr.* 2013;125(15-16):453-460.
2. Lesmana CRA, et al. Konsensus nasional penatalaksanaan hepatitis B di Indonesia. Perhimpunan Peneliti Hati Indonesia. 2017.
3. Pan Y, et al. Relationship between platelet parameters and hepatic pathology in patients with chronic hepatitis B infection – a retrospective cohort study of 677 patients. *J Int Med Res.* 2016;44(4):779-786.
4. Ekiz F, et al. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B. *J Clin Lab Anal.* 2011;25(3):162-165.
5. EL-Deeb, et al. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis C. *Afro-Egypt J Infect Endem Dis.* 2014;4(4):172-183.
6. Song JE and Kim DY. Diagnosis of hepatitis B. *Ann Transl Med.* 2016;4(18):1-6
7. Yano Y, et al. Hepatitis B virus infection in Indonesia. *World J Gastroenterol.* 2015;21(38):10714-10720
8. Muljono DH. Epidemiology of Hepatitis B and C in Republic of Indonesia. *Euroasian J Hepato-Gastroenterology.* 2017;7(1):55-59.
9. Ohkoshi S, et al. Natural regression of fibrosis in chronic hepatitis B. *World J Gastroenterol.* 2016;22(24):5459-5466.
10. Rockey DC. Liver fibrosis reversion after suppression of hepatitis B virus. *Clin Liver Dis.* 2016;20(4):667-679.

11. Weiskirchen R and Tacke F. Liver fibrosis: Which mechanisms matter? *Clin Liver Dis.* 2016;8(4):94-9.
12. Cheng JY and Wong GL. Advances in the diagnosis and treatment of liver fibrosis. *Hepatoma Res.* 2017;3(8):156.
13. Weiskirchen R, Weiskirchen S, and Tacke F. Recent advances in understanding liver fibrosis: Bridging basic science and individualized treatment concepts. *F1000Research.* 2018;7(0):1-17.
14. Hernandez-Gea V and Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol Mech Dis.* 2011;6:425-456.
15. Tsukada S, Parsons CJ, and Rippe RA. Mechanisms of liver fibrosis. *Clin Chim Acta.* 2006;364(1-2):33-60.
16. Weiskirchen R, Weiskirchen S, and Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. *Mol Aspects Med.* 2019;65:2-15.
17. Böttcher K and Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. *Adv Drug Deliv Rev.* 2017;121:3-8.
18. Shipley LC, Axley PD, and Singal AK. Liver Fibrosis : A Clinical Update. *Eur Med J Hepatol.* 2019;7(1):105-117.
19. Kumar R, et al. A practical clinical approach to liver fibrosis. *Singapore Med J.* 2018;59(12):628-633.
20. Parikh P, Ryan JD, and Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. *Ann Transl Med.* 2017;5(3):1-14.

21. Suk KT and Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. *World J Hepatol.* 2015;7(3):607-615
22. Castera L, Forns X, and Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol.* 2008;48(5):835-847.
23. Branchi F, et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. *World J Gastroenterol.* 2014;20(40):14568-14580.
24. Cardoso AC, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. *Liver Int.* 2012;32(4):612-621.
25. Bonder A and Afdhal N. Utilization of FibroScan in clinical practice. *Curr Gastroenterol Rep.* 2014;16(2):372.
26. Witters P, et al. Review article: Blood platelet number and function in chronic liver disease and cirrhosis. *Aliment Pharmacol Ther.* 2008;27(11):1017-1029.
27. Korniluk A, et al. Mean platelet volume (MPV): New perspectives for an old marker in the course and prognosis of inflammatory conditions. *Mediators Inflamm.* 2019;1-14.
28. Schmoeller D, et al. Mean platelet volume and immature platelet fraction in autoimmune disorders. *Front Med.* 2017;4:1-5.
29. Smith GS, Walter GL, and Walker RM. Clinical Pathology in Non-Clinical Toxicology Testing. In: Haschek and Rausseaux's Handbook of Toxicologic Pathology Third Edition. *Elsevier*; 2013;565-594.
30. Farias MG, et al. Definition of reference ranges for the platelet distribution width (PDW): A local need. *Clin Chem Lab Med.* 2010;48(2):255-257.

31. Amin MA, Amin AP, and Kulkarni HR. Platelet distribution width (PDW) is increased in vaso-occlusive crisis in sickle cell disease. *Ann Hematol.* 2004;83(6):331-335.
32. Vagdatli E, et al. Platelet distribution width: A simple, practical and specific marker of activation of coagulation. *Hippokratia.* 2010;14(1):28-32.
33. de Lédinghen V and Vergniol J. Transient elastography (FibroScan). *Gastroenterol Clin Biol.* 2008;32(1):58-67.
34. Heidelbaugh JJ and Bruderly M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. *Am Fam Physician.* 2006;74(5).
35. Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* 2018;67(1):328-357.
36. Baig S. Gender disparity in infections of hepatitis B virus. *J Coll Physician Surg Pakistan.* 2009;19(9):598-600.
37. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Hepatitis B. Stockholm: ECDC;2016.
38. Sirinawatien A, et al. Prevalence and determinants of significant liver fibrosis by vibration-controlled transient elastography in Thai chronic hepatitis B patients. *Int J Hepatol.* 2018;1-7.
39. Wong VWS, Chan HLY, and Wong GLH. Liver fibrosis progression in patients with chronic hepatitis B: a prospective study with paired transient elastography. *Hong Kong Med J.* 2017;23(4):23-26.
40. Mohamed MS, Bassiony MAA, and Mohamed AFE. The role of mean

- platelet volume in predicting severity and prognosis of liver cirrhosis in Egyptian patients. *Egypt J Intern Med.*2019;31(3):261-265.
41. Soeliauwan SS, Muhadi D, and Muthmainnah. Platelet Indices for predicting liver fibrosis in patients with chronic hepatitis B infection. *Indonesian J Clin Pathology Med Lab.* 2018;25(1):35-37.
  42. Hu Y, et al. Evaluation of mean platelet volume in patients with hepatitis B virus infection. *Int J Clin Exp Med.* 2014;7(11):4207-4213.
  43. Zhong LK, et al. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. *J Clin Lab Anal.* 2020;34(7):1-6.
  44. Anwar H, Mutmainnah M, and Samad IA. Analysis of platelet count on fibrosis degree in chronic hepatitis B patients. *Indones J Clin Pathol Med Lab.* 2018;24(2):165.
  45. Nwokediuko S. Quantitative platelet abnormalities in patients with hepatitis B virus-related liver disease. *Gastroenterol Res.* 2009;2(6):344-349.
  46. Karasu Z, et al. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. *Dig Dis Sci.* 2007;52(6):1535-1539.





**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 464/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 24 Agustus 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080389	No Sponsor	
Peneliti Utama	<b>dr. Irfan Adi Saputra</b>	Protokol	
Judul Peneliti	Hubungan Mean Platelet Volume dan Platelet Distribution Width dengan Fibrosis Hati pada Pasien Hepatitis B Kronik		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>18 Agustus 2020</b>
No Versi PSP	<b>1</b>	Tanggal Versi	<b>18 Agustus 2020</b>
Tempat Penelitian	<b>RSUP Dr.Wahidin Sudirohusodo dan RS Jejaring di Makassar</b>		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>24 Agustus 2020</b> sampai <b>24 Agustus 2021</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan